Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Colorcon
Moodys
Dow
Merck

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Litigation Details for Skelaxin (Metaxalone) Antitrust Litigation (E.D. Tenn. 2012)

See Plans and Pricing

« Back to Dashboard

Skelaxin (Metaxalone) Antitrust Litigation (E.D. Tenn. 2012)

Docket   Start Trial Date Filed 2012-05-17
Court District Court, E.D. Tennessee Date Terminated 2017-08-01
Cause 15:1 Antitrust Litigation Assigned To Curtis Lynn Collier
Jury Demand Both Referred To Christopher H. Steger
Parties BLUE CROSS BLUE SHIELD OF TENNESSEE, INC.; CARLOS A PARALITICCI; PAINTERS DISTRICT COUNCIL NO. 30 HEALTH & WELFARE FUND
Patents 6,407,128; 6,683,102; 7,122,566
Attorneys Christopher M Burke; J. Gerard Stranch , IV; James G Stranch , III; Joe P Leniski; Joseph M. Burns; Joseph P Guglielmo; Lori A Fanning; Luis E Minana; Mark M Sandmann; Marvin A Miller; Matthew E Van Tine; Michael A Anderson; Pamela B Slate; Tiffany R Reeves
Firms Branstetter Stranch & Jennings PLLC; Gibson & Sharps; Hill, Hill, Carter, Franco, Cole & Black P.C.; Jacobs, Burns, Orlove & Hernandez; Luis E. Minana & Associates LLC; Miller Law LLC; Patrick, Beard, Schulman & Jacoway, PC; Scott Scott LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Skelaxin (Metaxalone) Antitrust Litigation
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Skelaxin (Metaxalone) Antitrust Litigation (E.D. Tenn. 2012)

Date Filed Document No. Description Snippet Link To Document
2013-05-20 200 Memorandum & Opinion In June 2002, the PTO issued patent number 6,407,128 (the “‘128 patent”) with respect to the findings…Skelaxin. The patent on the active ingredient metaxalone (patent number 3,062,827 or the “‘827 patent”), which…rights to the ‘128 patent and the patent application for what would become the ‘102 patent (DPP Compl. ¶¶…give notice to the patent holder. Id. (citing 21 U.S.C. § 355(j)(2)(B)). The patent holder has the option…time the court hearing the patent infringement case finds that the patent is invalid or not infringed External link to document
2014-01-08 488 Exhibit 2 to Declaration 26. “Patents” means U.S. Patent No. 6,407,128, U.S. Patent No. 6,683,102, and U.S. Patent No. 7,122,566…,122,566. 27. “PTO” means the U.S. Patent and Trademark Office. 28. “Proposed External link to document
2013-01-04 85 Memorandum in Support of Motion States Patent and Trademark Office (“PTO”) issued U.S. Patent No. 6,407,128 (“the ’128 Patent”) in June…concealed in any way. A patent, the Orange Book listings of patents,20 and patent litigation records21 …Alleged Sham Patent Infringement Litigations and Unlawful Listing of Patents in the Orange… A. The Sandoz Patent Litigation and the ’102 Patent Case Were Not …also required to include the patent numbers and expiration dates of any patent (1) which claims the drug External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
McKesson
Medtronic
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.